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Abstract Different patterns of bonemarrow (BM) infiltration
by diffuse large B cell lymphomas (DLBCL) have been
described. A pure nodular pattern is uncommon, and the
pathologic features, as well as the clinical correlates of
DLBCL manifesting this pattern in the BM have not been
well characterized. We evaluated BM biopsies involved by
large B cell lymphomas diagnosed at our institute over an 11-
year period to assess the morphology, phenotype, cytogenetic
abnormalities, and clinical features of cases associated with
a nodular pattern. A distinct nodular pattern of BM involve-
ment was noted in 14 out of 55 (25%) cases. Although both
EBV+ and EBV− DLBCL with this pattern were identified,
a pure nodular pattern was significantly more common in
EBV+ DLBCL compared to EBV− DLBCL (8/9, 89%
versus 6/46, 13%; P=0.00002). The majority of EBV+
DLBCL associated with a nodular pattern had distinctive
morphologic features (polymorphic cellular infiltrate and
pleomorphic cytology), and CD30 expression was more
commonly observed in this group (P=0.0163). All EBV+
DLBCL and two out of six (33%) EBV− DLBCL had
nongerminal center phenotypes. No recurrent cytogenetic
abnormalities were detected in either group. Importantly, all
EBV+ DLBCL occurred in individuals with immune
dysfunction (organ transplant recipients, HIV infection) or
in those >50 years of age. Our study indicates a much higher
predilection for EBV+ DLBCL to involve the marrow in a
nodular pattern compared to EBV− cases and highlights
similarities in the morphologic pattern of BM involvement
by previously recognized subsets of immunodeficiency-
related EBV+lymphomas and the newer entity of “EBV+
DLBCL of the elderly.”
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Introduction
Bone marrow (BM) examination is an integral part of the Ann
Arbor staging system for B cell non-Hodgkin lymphomas (B-
NHL). Bone marrow involvement indicates stage IV disease,
which is an adverse prognostic factor in the International
Prognostic Index (IPI), but it is also independently associated
with a worse prognosis [1]. The frequency of BM involve-
ment by B-NHL varies according to disease subtype.
Marrow infiltration is more commonly observed in patients
with low grade B-NHL, ranging from 30% for marginal zone
lymphomas to virtually 100% for chronic lymphocytic
leukemias [2–7], compared to diffuse large B cell lympho-
mas (DLBCL; 8–35%) [2, 3, 8–13]. Differences in the
frequency of BM involvement by DLBCL, with regard to
their phenotype or association with Epstein–Barr virus
(EBV) infection, are currently unclear. Characteristic pat-
terns of BM infiltration by different subtypes of B-NHL
have also been reported, with the paratrabecular pattern
more commonly seen in follicular lymphoma, the interstitial
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diffuse and/or nodular pattern frequently observed in chronic
lymphocytic leukemia/small lymphocytic lymphoma and
lymphoplasmacytic lymphoma, and the sinusoidal pattern
most often associated with splenic marginal zone lymphoma
[2, 14, 15]. Only a few studies have described different
patterns of BM involvement by DLBCL [2, 6, 16]. These
include diffuse, interstitial, paratrabecular, nodular, and
mixed patterns. A pure nodular pattern appears to be one
of the least common, observed in 0–23% of cases [2, 4–6,
16], and DLBCL manifesting this pattern of BM infiltration
have not been well-characterized. Thus, we undertook this
study to assess the morphology, phenotype, associated
cytogenetic abnormalities, and clinical features of DLBCL
with a distinct nodular pattern of BM involvement. We
observed nodular BM infiltrates in both EBV− and EBV+
DLBCL; however, this pattern was significantly more
common in EBV+ DLBCL. All of the EBV+ DLBCL in
our series occurred in immunosuppressed patients and
included cases representing the recently described entity of
EBV+ DLBCL of the elderly.
Methods
Case selection and clinical characteristics
A search of our departmental database was performed to
identify BM biopsies, which had infiltrates of DLBCL over
a period of 11 years (January 1997–December 2007).
Morphologic features were assessed using H&E stained
sections of Bouin’s fixed paraffin-embedded BM biopsies.
The pattern of BM involvement was analyzed to identify
cases with pure nodular infiltrates of DLBCL. A distinct or
pure nodular pattern was defined as the presence of well-
delineated or circumscribed aggregates of large neoplastic
lymphocytes with <10% of the neoplastic cells demonstrat-
ing a different pattern of infiltration (i.e., single scattered
cells) [2]. The corresponding formalin-fixed paraffin-
embedded lymph node (LN) or soft tissue biopsies of the
DLBCL, where available, were also evaluated to character-
ize architectural and cytologic features.
Data regarding patient demographics, EBV viral load
and/or serology, immune status, immunosuppressive regi-
men, chemotherapy and/or radiation therapy, and clinical
outcomes were obtained from our laboratory information
system. Epstein–Barr virus reactivation was defined as
detection of >100 copies per milliliter of EBV antigen by
polymerase chain reaction (PCR) analysis.
Immunohistochemistry and in situ hybridization
Immunohistochemical stains were performed on the BM
biopsies and LN or soft tissue biopsies, using the primary
antibodies listed in Table 1, after heat-induced antigen
retrieval, and were visualized with Envision plus (DAKO,
Carpinteria, California, USA) and DAB. Cases were scored as
positive for the antigen of interest if >30% of the neoplastic
cells expressed it. Based on the expression of CD10, BCL6,
and IRF4, the DLBCL were classified as either germinal
center (GC) type (CD10+ or CD10−/BCL6+/IRF4−) or non-
GC type (CD10−/BCL6+/ IRF4+ or CD10−/BCL6−/IRF4+)
[17]. Semiquantitative assessment of the reactive T cells
within the nodules of DLBCL was performed on CD3-
stained sections (<10%=mild, >10–50%=moderate, >50%=
marked).
In situ hybridization for EBV-encoded small RNAs
(EBER) was performed using the supplied protocol
(INFORM EBER, Ventana, Tuscon, Arizona, USA). Cases
were considered EBV+ when the vast majority (>90%) of
neoplastic cells expressing one or more of the B cell
antigens (CD20/PAX5/OCT2) demonstrated a positive
signal by EBER.
Cytogenetic analysis
Giemsa banding was performed on metaphase preparations
obtained after short term (12 h) unstimulated cultures
of the BM aspirate, LN, or soft tissue biopsies using
standard methods. Karyotypes were described according to
the International System for Human Cytogenetic Nomen-
clature [18]. Fluorescence in situ hybridization (FISH) was
performed on methanol/acetic acid fixed cells using
immunoglobulin heavy chain gene (IGH), BCL6(3q27),
and c-MYC(8q24) dual color break-apart probes (VYSIS,
Downers Grove, Illinois, USA) or locus specific probes for
TP53/ATM (VYSIS) and BLIMP1(PRDM1)(6q21) [19], as
indicated, according to standard protocols. Fluorescence
signals were captured after analyzing 200–300 cells and
counterstaining with DAPI using the Cytovision Imaging
system attached to a Nikon Eclipse 600 microscope
(Applied Imaging, Santa Clara, California, USA).
Immunoglobulin heavy chain gene rearrangement
Polymerase chain reaction analysis to detect IGH variable
region gene rearrangement was performed on bone marrow
aspirates and LN or soft tissue biopsies, using the Biomed-2
primers (IVS Gene Clonality Assay Kit, InVivo Scribe
Technologies, San Diego, CA, USA).
Statistical analysis
The observed data were tested for normalcy using a
Kolmogorov–Smirnov test. Statistical significance of differ-
ences between groups was calculated using the one-tailed
Student’s t test with a significance threshold of P<0.001 or
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Fisher’s exact probability test, and a P value of <0.05 was
considered significant.
Results
Case and patient characteristics
Fifty-five cases of DLBCL involving the BM were
diagnosed at our institute during the study period, and the
most common primary pattern of BM involvement was
diffuse (23/55, 42%), followed by nodular (18/55, 32%),
interstitial single-cell (12/55, 22%), and paratrabecular (2/55,
4%). Of the 18 cases with a nodular component, four
were eliminated since they exhibited a mixed pattern and
did not fulfill our definitional criteria (three had a
component of diffuse infiltrate and one had numerous
single scattered cells). Thus, 14 of 55 (25%) BM biopsies
exhibited a pure nodular pattern. In all, except one case,
besides the nodular aggregates, the minor component of
single scattered or small clusters of neoplastic cells,
represented <5% of the DLBCL infiltrate; one case had
an additional component of scattered neoplastic cells
approaching 10% of the total DLBCL infiltrate. EBV−
DLBCL with a nodular pattern accounted for six of 46 of
all EBV− cases (13%), whereas EBV+ DLBCL with a
nodular pattern represented eight of nine (89%) of all
EBV+ cases involving the BM (P=0.00001967868), only
one EBV+ DLBCL with a non-nodular pattern (single cell
interstitial infiltrate) was seen in our series.
Table 1 Immunohistochemical staining profile of DLBCL with a nodular pattern of bone marrow infiltration
Antibody, clone, company EBV+ (n=8) EBV− (n=6)
Case number 1 2 3 4 5 6 7 8 9 10 11 12 13 14
CD45, 2B11+PD7/26, DAKO, Carpinteria,
California, USA
+ + + + + + + + + + + + + +
CD20, L26, DAKO − + + + + + + + + + + + + +
PAX5, 24, Cell Marque, Rocklin, California, USA − + + + + + + + + + + + + +
CD79a, JCB117, DAKO + + + + + + + + + + + + + +
Pu-1, G148-74, BDPharm, Franklin Lakes, New
Jersey
+ + + − − + + − + + + + + +
OCT2, N/A, Santa Cruz + + + + + + + + + + + + + +
CD10, Calla (56C6), Novacastra, Newcastle upon
Tyne, UK
− − − − − − − − + − − − + −
BCL6, PG-B6P, DAKO − + − − + + − − + + − + + +
IRF4, MUM1p, DAKO + + + + + + + + − − + − − +
CD138, M115, DAKO
CD30, Ber-H2, DAKO + − + + + + + + − − − − − +
BCL2, 124, DAKO + − − + + + + + + + + + + +
CD15, LEUM1, DAKO − − − − − − − − − − − − − −
CD5, CD5/54/P6, DAKO − − − − − − − − − − − − − −
Fascin, 55 K2, DAKO − − + − − − − − − − − − − −
p53a, BP53-12-1, BIOGENEX, San Ramon,
California, USA
+ − − − − − − − − + − − − +
Ki-67b, MIB1, DAKO 90 80 80 50 80 60 90 70 30 90 50 60 70 80
HHV8 (LANA), 13B10, Cell Marque − − − − − − − − − − − − − −
EBNA2, PE2, DAKO − + − − − + − − − − − − − −
LMP1, CSI-4DAKO + + + + + + + + − − − − − −
EBER, in situ hybridization; Ventana, Tucson,
Arizona, USA
+ + + + + + + + − − − − − −
CD3c, F7.2.38, DAKO 1 1 2 1 2 1 3 3 1 1 2 1 3 1
CD4:CD8dCD4, SP35, Cell Marque CD8, C8/
144B, DAKO
1:10 1:2 1:2 1:7 1:2 1:3 1:1 1:2 1:2 1:2 1:1 1:2 1:2 1:1
a p53 considered positive if >30% of the neoplastic cells demonstrated nuclear expression
b Ki-67 expressed as percentage of neoplastic cells
c CD3 staining profile refers to nonneoplastic T cells within the nodules, 1=mild, 2=moderate, and 3=marked
d CD4:CD8 ratio refers to relative proportions of reactive T cells within the nodules
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Clinical characteristics of the patients are described in
Table 2. All patients presented with de novo DLBCL, except
one patient with an EBV+ DLBCL who had a history of B-
NHL, not otherwise specified, 14 years prior to the current
BM biopsy. The morphology was identical in the previous
BM biopsy; however, no material was available to perform in
situ hybridization for EBER in the prior biopsy. A male
predominance was observed for EBV+ DLBCL (M:F=5:3),
while patients with EBV− DLBCL had an equal gender
distribution (M:F=3:3). There was no significant difference in
the median age of patients that had EBV+ or EBV− DLBCL
(66 years versus 59 years, range 3–83 years and 34–84 years,
respectively; P=0.4192). Additionally, no difference in the
mean age of patients with EBV− nodular DLBCL, and those
that had EBV− DLBCL with other patterns of BM
involvement was noted. No significant difference in lactate
dehydrogenase (LDH) levels, IPI, Eastern Cooperative
Oncology Group (ECOG) performance status, or response
rates was seen between the two groups. EBV+ DLBCL with
a nodular pattern were seen exclusively in immunocompro-
mised patients: HIV+ (n=2), solid organ transplant (n=3),
and old age (>50 years, n=3); two of the recipients of solid
organ transplants were >50 years of age, while five of six
(83%) individuals with EBV− nodular DLBCLwere >50 years
of age, but none of the latter had any apparent immune
dysfunction. None of the patients had a concurrent (or prior) T
cell lymphoma or an autoimmune or collagen vascular disease,
and with the exception of PTLD patients, none received
immunosuppressive medication (e.g. methotrexate).
At diagnosis, PCR-based EBV viral load assessment was
performed in five of eight patients with EBV+ DLBCL and
in two of six patients with EBV− DLBCL. An elevated
serum EBV viral load was noted at the time of diagnosis in
all five EBV+ DLBCL (range 411,000–1,352,000 copies
per milliliter; mean 852,000). Epstein–Barr virus was
undetectable on follow-up evaluation in two of the five
cases, both PTLD patients (1 month and 1 year after
diagnosis). None of the tested EBV− cases had measurable
viral loads at the time of diagnosis.
Morphology and phenotype
The nodules in all eight EBV+ DLBCL were discrete and
had rounded contours, with numerous admixed histiocytes,
small lymphocytes, occasional plasma cells, and variable
numbers of neoplastic cells (Fig. 1). Histiocyte-rich nodules
(highlighted with a stain for PGM-1), with histiocytes
comprising >50% of the nodule cellularity, were seen in
five of eight (62%) cases. The nodules varied in size, both
within the same biopsy and between different biopsies,
ranging from small (nodules occupying ≤1/2 of a high
power field, 400×) to large and expansile (nodules
occupying at least one high power field; Table 3). BM
biopsies in three of eight cases (38%) showed only
interstitial nodules, and only paratrabecular nodules were
seen in three cases (38%); two (25%) had both para-
trabecular and interstitial nodules (Table 3). A single case
showed one nodule in which the neoplastic cells displayed
an angiocentric pattern with accompanying coagulative
necrosis (Fig. 2f); while in three cases, the nodules had
single-scattered apoptotic cells. Neoplastic cells were
quantified based on CD20, PAX5 and/or OCT2 staining
as assessment of H&E stained slides always underestimated
the number of neoplastic cells. In the majority of biopsies
(5/8, 62%), large neoplastic cells comprised a minority of
the cellular elements (20–30%) that were either seen as
scattered cells at the periphery (targetoid pattern) or ran-
domly distributed throughout the nodules (Fig. 3). In the
remaining cases (3/8, 38%), neoplastic cells comprised
>30% of the nodular cellular infiltrate (Fig. 2h). The
neoplastic cells had centroblastic morphology (large lym-
phocytes with scant to moderate amphophilic cytoplasm,
round to ovoid nuclear contours, fine chromatin, and
multiple small nucleoli) in only two of eight (25%) cases
(Fig. 2h), with the majority (6/8, 75%) displaying pleomor-
phic cytologic features (large lymphocytes with angulated
or irregular nuclear contours) and bizarre or Reed–
Sternberg (RS)-like cells were identified in four (66%)
of the latter biopsies (Fig. 2d).
Variables EBV+ cases (n=8) EBV− cases (n=6)
Sex (male/female) 5/3 3/3
Age, median (range; years) 66 (3–83) 59 (34–84)
Older than 60 6 (75%)a 3 (50%)a
ECOG PS 2–4 3 (38%)a 1 (17%)a
Bsymptoms, presence 6 (75%)a 3 (50%)a
LDH elevated 8 (100%)a 6 (100%)a
Ann Arbor stage III/IV 8 (100%)a 6 (100%)a
Extranodal involvement (>1 site) 4 (50%)a 2 (33%)a
IPI,high intermediate/high 6 (75%)a 4 (66%)a
Table 2 Clinical characteristics
of patients with nodular




performance status, LDH lactate
dehydrogenase, IPI International
Prognostic Index
a Number of cases (%)
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In contrast, nodules of the six EBV− DLBCL had irregular
contours in the majority of cases (4/6, 66%; Fig. 1). Only a
few admixed histiocytes were noted (10–30% of all cellular
elements within the nodules) that were present in similar
numbers as the adjacent uninvolved marrow, and two cases
had fewer histiocytes within the nodules compared to the
uninvolved marrow, imparting a “negative image” (Fig. 4f).
The nodules also had a higher number and density of
neoplastic cells compared to most of the EBV+ cases (Fig. 1;
Table 3). In all EBV− DLBCL, the neoplastic cells
comprised at least 50% of the cellular elements, and in the
majority (4/6, 66%), large cells comprised >80% of the
nodular cellular infiltrate (Fig. 4e). Half of the biopsies (n=
3) showed only interstitial nodules, while the remaining half
showed both interstitial and paratrabecular nodules. The
neoplastic cells in the majority of cases (5/6, 83%) demon-
strated centroblastic morphology; only one (17%) DLBCL
had pleomorphic cytology. The numbers of admixed T cells
were variable in EBV+, as well as EBV– DLBCL, and most
cases showed a predominance of CD8+ T cells. The inverted
CD4:CD8 ratio was especially marked in the 2 EBV+ HIV-
associated DLBCL (Table 1). None of the nodules showed
evidence of follicular dendritic cell meshworks as assessed
by immunohistochemical stains for CD21 and CD23.
Fig. 1 EBV+ DLBCL of the elderly involving the BM in a nodular
pattern (case number 7). a BM shows a well-defined paratrabecular
nodular infiltrate, clearly visible at low magnification (H&E, 40×). b
The polymorphic cell population including histiocytes, small lympho-
cytes, and intermixed neoplastic cells is demonstrated at intermediate
magnification (H&E, 200×), while c high magnification highlights
pleomorphic cytology and occasional RS-like cells (H&E, 400×).
EBV− DLBCL with a nodular pattern (case number 12). d BM
biopsy shows less conspicuous nodules delineated by arrowheads
(H&E, 40×). e Intermediate (H&E, 200×) and f high magnification
(H&E, 400×) images show a high proportion of centroblast-like cells
within the nodules
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In 11 of 14 (79%) cases, corresponding LN or tissue
biopsies were available. Of the seven cases of EBV+
DLBCL available for review, four occurred at extranodal
sites (two gastrointestinal tract, one liver, and one kidney),
while three were LN-based (one axillary, one mediastinal,
and one cervical). Four cases showed variable areas of a
polymorphic infiltrate, comprising histiocytes, plasma cells,
and small-sized reactive lymphocytes with scattered neo-
plastic cells being the minority component (Fig. 2a). The
two PTLD cases were of the monomorphic type, and the
LNs showed near total effacement by sheets of large
neoplastic lymphocytes, one had pleomorphic neoplastic
cells (Fig. 2i), while the other displayed plasmacytoid
features. Overall, pleomorphic neoplastic cells were seen in
five cases, and numerous anaplastic or RS-like cells were
seen in the majority (4/7, 57%) of cases, similar to findings
in the BM biopsies (Fig. 2c). Four of the six EBV−
DLBCL, with tissue biopsies available for review, were
equally distributed between those occurring at extranodal
sites (one testes and one retroperitoneal mass) and LNs
(one axillary and one cervical). All these cases displayed
centroblastic morphology. As in the corresponding BM
biopsies, only a minimal infiltrate of admixed histiocytes
was observed. One of the two EBV− nodular BM DLBCL,
without available tissue biopsies, demonstrated pleomor-
phic morphology.
All DLBCL expressed one or more B lineage antigens
(CD20, PAX5, OCT2) (Table 1). All EBV+ DLBCL (n=8)
were EBER+ by in situ hybridization and had non-GC
phenotypes, while two of six (33%) and four of six (66%)
EBV– DLBCL had non-GC and GC phenotypes, respec-
tively (Table 3). The neoplastic cells of EBV+ DLBCL
more commonly expressed CD30 compared to EBV–
DLBCL (7/8, 88% versus 1/6, 17%; P=0.016317; Fig. 4d).
All EBV– DLBCL were fascin-negative, while only
one of eight (12%) EBV+ DLBCL showed weak fascin
staining. Six of eight (75%) EBV+ DLBCL had a type II
viral latency pattern (LMP1+ and EBNA2−), and two cases
(25%) displayed type III latency (LMP1+ and EBNA2+),
both of the latter were PTLDs. In the latter, the number of
EBER+ cells was greater than the EBNA2+ and LMP1+
cells combined, and nonoverlapping EBNA2+, and LMP1+
subsets were also seen, consistent with the presence of cell
populations with different, as well as transitional, EBV
latency types. None of the cases showed any staining for
LANA.
Cytogenetic analysis
In 12 of 14 (86%) cases, either BM aspirates or LN/soft
tissue biopsies were submitted for cytogenetic analysis. Of
these, seven cases had abnormal karyotypes, and all but one






































































































































































































































































































































































































































































































Virchows Arch (2009) 455:323–336 329
common cytogenetic aberrations were rearrangements of
IGH (14q32) detected in five cases (71%). Two cases (one
EBV+ and one EBV−), both with non-GC phenotypes,
showed t(8;14)(q24;q32) indicative of balanced reciprocal
translocations involving IGH and c-MYC. One EBV+
DLBCL showed t(14;19)(q32;q13) involving IGH, and the
region encoding BCL3 and one EBV− DLBCL demon-
strated t(3;14)(q27;q32) confirmed to represent a transloca-
tion involving IGH and BCL6. An EBV− DLBCL showed
rearrangement of IGH only detected by FISH; however, due
to the complexity of the karyotype, the partner could not be
determined (FISH excluded BCL6 and c-MYC).
Immunoglobulin heavy chain gene rearrangement
In seven of 14 (50%) cases, PCR analysis for IGH variable
region gene rearrangement was performed, and clonal
products were detected in six of seven (86%) cases (Table 3).
Discussion
Bone marrow involvement by DLBCL is less common than
low grade B-NHL and occurs in 8–35% of cases [2, 3, 8–
13]. However, EBV-associated DLBCL, which represent a
small subset of DLBCL (8–12%) [10, 20–24] were shown
to have a slightly greater proclivity for the BM (39%) in a
recent study [10], compared to EBV − DLBCL. Similar to
low grade B-NHLs, different morphologic patterns of BM
involvement by DLBCL have been described, which
include a predominant or near exclusive presence of diffuse
(15–50%), paratrabecular (0–53%), nodular (0–23%), or
single cell (17–24%) infiltrates of neoplastic cells [2, 4–6,
13, 16]. Similar patterns and frequencies of marrow
involvement by DLBCL were also observed in our series.
We decided to focus on DLBCL with a pure nodular pattern
in this study since little is known about the phenotypic and
clinical spectrum of such cases. A nodular pattern of BM
infiltration was noted in 25% of all our cases with BM
involvement by DLBCL, and although both EBV− and
EBV+ cases were observed, the latter predominated. Of
interest, among all cases of EBV+ DLBCL with BM
involvement, the vast majority (89%) exhibited a nodular
pattern, and EBV+ nodular DLBCL were exclusively seen
in patients with documented (organ transplantion, HIV
infection) or presumed (old age) immune dysfunction.
Differences in the morphologic, phenotypic, and clinical
characteristics of EBV+ and EBV– DLBCL with a nodular
pattern of BM infiltration were also noted.
EBV+ nodular DLBCL had distinctive morphologic
features. The nodules were well circumscribed, and the
neoplastic cells usually represented a minor component
scattered within a heterogenous population of nonneoplastic
inflammatory cells, including histiocytes in most cases.
Pleomorphic cytology was quite common, and RS-like cells
were observed in 50% of cases. In contrast, the nodules of
EBV− DLBCL had more irregular contours, and centroblast-
like neoplastic cells comprised the major cellular component
in the majority of cases. Lymph node and soft tissue biopsies
of the EBV+ DLBCL displayed features similar to those
observed in the BM with at least some areas demonstrating
neoplastic cells scattered within a polymorphic nonneoplastic
background, while all LN biopsies of EBV− DLBCL
evaluated showed diffuse infiltrates of centroblast-like cells,
similar to what is seen in routine cases of DLBCL.
All EBV+ and one third of the EBV− DLBCL had non-
GC phenotypes, and a significant number of EBV+ DLBCL
showed CD30 expression by at least a proportion of neo-
plastic cells compared to EBV − DLBCL, in agreement
with prior studies [22, 25]. Staining for fascin, a protein
involved in the formation of dendritic processes that is
expressed by RS cells in virtually all cases of classical
Hodgkin lymphoma (CHL) [26], and approximately 50% of
anaplastic large cell lymphomas [27], was seen in the BM
and corresponding LN biopsy in only one (13%) of our
EBV+ DLBCL, similar to the frequency reported previously
[27]. Previous studies of EBV+ DLBCL in PTLD patients
have shown high frequencies (36–64%) of type III latency
profiles [28, 29]. Lower frequencies of this latency type have
been reported in HIV patients (41–50%) [30, 31]. All, except
two of the EBV+ cases in our series, displayed type II
latency. Both PTLDs, which were of the monomorphic
subtype (DLBCL), exhibited type III latency profiles, but
populations of cells with different latency types were seen in
these cases, similar to previous observations [28, 29]. Our
three cases of EBV+ DLBCL of the elderly (see below)
showed type II latency, which is the more common latency
profile described in these lymphomas [23, 25]. Type III
Fig. 2 EBV+ DLBCL of the elderly (case number 8). An area
showing neoplastic lymphocytes scattered in a polymorphic non-
neoplastic background in the a LN (H&E, 200×) with a similar pattern
in the b corresponding bone marrow biopsy (H&E, 400×). EBV+
DLBCL of the elderly (case number 3). Markedly pleomorphic
neoplastic and RS-like cells in the c LN (H&E, 200×) and d
corresponding bone marrow biopsy (H&E, 400×). EBV+ DLBCL of
the elderly (case number 7). A diffuse infiltrate of large neoplastic
cells is evident in the e LN (H&E, 200×) while the f corresponding
BM biopsy exhibits angiocentricity with cellular debris and coagu-
lative necrosis (H&E, 400×). EBV+ DLBCL in an HIV patient (case
number 4). A high proportion of neoplastic cells are present in the g
LN (H&E, 200×) and h corresponding bone marrow biopsy (H&E,
400×). EBV+ DLBCL in a PTLD patient (case number 2). Sheets of
neoplastic cells consistent with monomorphic type of PTLD (DLBCL)
are seen in the i LN (H&E, 200×), the j corresponding BM biopsy
shows a moderate infiltrate of nonneoplastic cellular elements
(H&E, 400×)

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latency has, however, been described in a small proportion of
such cases (14–36%) [12, 20, 22, 23, 25, 32].
An interesting finding in our study relates to the presence of
EBV+ DLBCL that fulfill the criteria of the recently
recognized entity termed EBV+ DLBCL of the elderly [15,
23, 32, 33]. The current World Health Organization
classification defines these lymphomas as those occurring
in patients >50 years old without any known predisposing
Fig. 3 Distribution patterns of CD20+ and EBER+ neoplastic cells within nodules in the bone marrow biopsies in cases of EBV+ DLBCL
(100×). Neoplastic cells are scattered throughout the nodules (a, c) or seen in a targetoid pattern at the periphery of the nodule (b, d)
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immunodeficiency [15, 23, 32, 33]. A recent survey of EBV-
associated lymphomas by Cho et al. described 29 patients
with EBV+ DLBCL, 24 of whom were elderly or had a
prior history of hepatitis B or C virus infection, tuberculosis,
or CHL, suggesting decreased immunity associated with old
age and/or environmental cofactors as contributors to
lymphomagenesis [20]. It is thought that age associated
immune dysfunction, a phenomenon described as “immune
senescence,” predisposes older individuals to EBV+ lym-
phomas [34]. Similarities of EBV+ DLBCL of the elderly to
B-NHL arising in immunodeficient or immunocompromised
patients have been previously described, including a propen-
sity for extranodal disease and the morphologic spectrum of
lymphoproliferations, ranging from polymorphic lymphomas
resembling polymorphic PTLDs to large cell monomorphic
lymphomas indistinguishable from conventional DLBCL
[12, 15, 20, 23, 25, 32, 33, 35, 36]. Although, BM
involvement has been documented in EBV+ DLBCL of the
elderly, to the best of our knowledge, the patterns of BM
involvement have not been described. It remains to be seen
whether a nodular pattern is the most prevalent pattern of
BM involvement in this entity, as seen in our study. Virtually,
all prior studies of EBV+ DLBCL have been reported from
Asia, whereas, all our three patients were Caucasian and of
European descent. Moreover, in contrast to the Asian
experience, our cases did not show extranodal involvement.
The morphologic and phenotypic features of our nodular
DLBCL also showed an overlap with other types of B cell
malignancies, which include T cell/histiocyte-rich large B
cell lymphoma (THRLBCL), especially the micronodular
variant [37], lymphomatoid granulomatosis (LG), and
CHL. Bone marrow involvement, although rare in some
of these entities, has been described [38, 39]. The paucity
of neoplastic cells and the presence of a polymorphic
background, often rich in histiocytes and small reactive T
cells, in all these entities, can pose a diagnostic challenge,
especially, when reviewing BM biopsies. T cell/histiocyte-
rich large B cell lymphomas are usually EBV−; however,
rare cases of EBV+ THRLBCL with CD30+ neoplastic
cells showing RS-like morphology have been described
[40]. However, by definition, the diagnosis of THRLBCL
requires the presence of at least a 90% component of
nonneoplastic cells, without any aggregates or sheets of
large neoplastic cells [15]. All our DLBCL, though rich in
nonneoplastic cells, had clusters and/or sheets of neoplastic
cells that comprised at least 20% of all cellular elements of
the nodules of EBV+ DLBCL and >50% of the EBV−
DLBCL. Lymphomatoid granulomatosis also has a poly-
morphic infiltrate with variable numbers of large EBV+
lymphocytes that may also express CD30. However, these
lymphoproliferations show angiocentricity and/or angiodes-
truction and although occasional bizarre lymphocytes may
be seen, classic RS-like cells are infrequent [15]. Angio-
centricity and angiodestruction with associated coagulative
necrosis was observed focally in only one BM biopsy of
our EBV+ DLBCL, within a nodular aggregate that had a
large proportion of neoplastic cells. Nodal involvement,
which is rare in LG, is usually characterized by a
predominance of small-sized T cells in the background,
while the LN biopsy of the aforementioned case showed a
diffuse infiltrate of predominantly large neoplastic cells,
and there was no evidence of extranodal disease arguing
against the possibility of LG [41]. Classical Hodgkin
lymphoma often presents as nodular polymorphic lympho-
histiocytic infiltrates with infrequent CD30+ RS-like cells
in the BM [42]. RS cells in CHL coexpress CD30 and
CD15 in the majority of cases (80%), are uniformly
positive for fascin, and although a minority can express
bright CD20 (30%), they usually do not express OCT2 or
PU-1 [15, 26]. The CD30+ RS-like cells in our EBV+
DLBCL were uniformly negative for CD15, expressed
CD20 in the majority of cases (88%), expressed PU-1 in
50%, and fascin was only expressed in one case. Moreover,
all except one case tested, showed clonal immunoglobulin
gene rearrangements, which are less commonly detected in
CHL by the current assays. The morphologic and pheno-
typic features of one of our EBV+ cases was similar to the
so-called mediastinal gray zone lymphomas, although there
was no evidence of mediastinal disease and the latter tend
to be EBV− [43]. Methotrexate-related lymphoproliferative
disorders can also display similar features, but none of our
patients received methotrexate therapy [44]. Although, even
nonneoplastic disorders (especially infectious mononucleo-
sis) could morphologically mimic the findings we describe,
involvement of the bone marrow is exceptionally rare in
these situations. Our study highlights the utility of an
extensive immunophenotypic panel, examination of tissue
from other sites, and correlation with the clinical features in
order to distinguish between these different diagnostic
considerations when a nodular pattern of DLBCL is
encountered in BM biopsies.
Cytogenetic analysis demonstrated complex cytogenetic
aberrations in approximately 50% of our EBV+ and EBV–
DLBCL evaluated, but recurrent cytogenetic abnormalities
were not observed. Translocations involving IGH (14q32)
were the most frequently encountered abnormality, detected
in almost half of the cases with cytogenetic abnormalities;
however, the partners varied. Translocations of IGH and c-
MYC were detected in one case each of EBV+ and EBV−
DLBCL. Both had complex karyotypes and non-GC
phenotypes, effectively ruling out a diagnosis of Burkitt
lymphoma. Intriguingly, an EBV+ DLBCL showed a t
(14;19)(q32;q13) on karyotypic analysis, potentially in-
volving the BCL3 locus, which has been previously
reported in a variety of B-NHLs [45]; however, FISH was
not performed to confirm involvement of BCL3 in this case.
Virchows Arch (2009) 455:323–336 333
334 Virchows Arch (2009) 455:323–336
Cytogenetic findings have not been previously described in
surveys of EBV+ DLBCL of the elderly. Our results
suggest that the spectrum of cytogenetic aberrations in
these cases might be similar to conventional DLBCL [46].
All, but one of our cases, showed clonal IgH gene
rearrangement products by PCR analysis. Addition of
PCR assays for Ig light chains might have increased the
yield of our clonal cases, since cases have been described
that show clonality only on using light chain (IgK)
primers [47].
Lastly, but importantly, our study suggests investigation
of the patient’s immune status and evaluation for EBV
infection if one observes a nodular pattern of BM
involvement by DLBCL with the described features.
Determination of EBV status is clinically relevant as
multiple studies have demonstrated that EBV+ DLBCL
patients have significantly lower overall survival rates,
compared to individuals with EBV– DLBCL [10, 22, 24,
33]. We did not see any significant difference in ECOG
status, LDH levels, IPI, or clinical outcomes between
EBV+ and EBV– DLBCL patients, which might be
attributable to our small sample size and/or selection of
patients with advanced stage disease (BM involvement).
High mortality was seen in both groups, and the small
number of patients precludes any assessment of the type of
therapy. Since immunosuppressed patients with T cell
dysfunction are at risk for “reactivation” of EBV and
subsequent development of EBV-associated lymphoproli-
ferative disorders, viral load monitoring in patients with
EBV+ PTLDs is performed to detect early disease
recurrence and response to treatment [48, 49]. EBV viral
load assessment performed in five of our patients at
diagnosis of EBV+ B-NHL, which included individuals
with PTLD, HIV associated DLBCL, and EBV– DLBCL of
the elderly, showed evidence of viral reactivation. Future
studies need to investigate the utility of serial serologic or
EBV viral load monitoring, as performed in PTLD patients,
in detecting early disease recurrence in EBV+ DLBCL of
the elderly. Clinical trials using targeted therapies that
induce the lytic form of infection in EBV+ lymphoid
malignancies in conjunction with gancyclovir treatment
have shown promising results [50]. This strategy might also
be useful in treating EBV+ DLBCL of the elderly. Since
altered lymphocyte development and function contribute to
immunosenescence in the elderly, recently proposed treat-
ment approaches aimed at rejuvenating the immune system
and augmenting innate immunity in the elderly might be
alternative therapeutic options [51].
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